Supernus Pharmaceuticals Inc (SUPN) - Total Assets
Based on the latest financial reports, Supernus Pharmaceuticals Inc (SUPN) holds total assets worth $1.43 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Supernus Pharmaceuticals Inc - Total Assets Trend (2008–2025)
This chart illustrates how Supernus Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Supernus Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
Supernus Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Supernus Pharmaceuticals Inc's total assets of $1.43 Billion consist of 44.4% current assets and 55.7% non-current assets. Review SUPN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.8% |
| Accounts Receivable | $187.80 Million | 12.9% |
| Inventory | $82.39 Million | 5.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $569.46 Million | 39.2% |
| Goodwill | $124.88 Million | 8.6% |
Asset Composition Trend (2008–2025)
This chart illustrates how Supernus Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Supernus Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Supernus Pharmaceuticals Inc's current assets represent 44.4% of total assets in 2025, a decrease from 90.1% in 2008.
- Cash Position: Cash and equivalents constituted 8.8% of total assets in 2025, down from 68.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 2.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 39.2% of total assets.
Supernus Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Supernus Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Supernus Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.08 | 2.58 | 2.85 |
| Quick Ratio | 1.84 | 2.43 | 2.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $376.12 Million | $452.51 Million | $433.66 Million |
Supernus Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Supernus Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.65 |
| Latest Market Cap to Assets Ratio | 1.65 |
| Asset Growth Rate (YoY) | 6.2% |
| Total Assets | $1.45 Billion |
| Market Capitalization | $2.40 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Supernus Pharmaceuticals Inc's assets above their book value (1.65x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Supernus Pharmaceuticals Inc's assets grew by 6.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual total assets of Supernus Pharmaceuticals Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.45 Billion | +6.18% |
| 2024-12-31 | $1.37 Billion | +7.08% |
| 2023-12-31 | $1.28 Billion | -24.95% |
| 2022-12-31 | $1.70 Billion | +0.79% |
| 2021-12-31 | $1.69 Billion | +12.30% |
| 2020-12-31 | $1.50 Billion | +29.63% |
| 2019-12-31 | $1.16 Billion | +18.66% |
| 2018-12-31 | $977.81 Million | +130.36% |
| 2017-12-31 | $424.46 Million | +37.11% |
| 2016-12-31 | $309.57 Million | +64.03% |
| 2015-12-31 | $188.73 Million | +37.25% |
| 2014-12-31 | $137.51 Million | +23.89% |
| 2013-12-31 | $111.00 Million | +18.09% |
| 2012-12-31 | $93.99 Million | +74.93% |
| 2011-12-31 | $53.73 Million | +14.30% |
| 2010-12-31 | $47.01 Million | -41.16% |
| 2009-12-31 | $79.90 Million | +3.59% |
| 2008-12-31 | $77.13 Million | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more